These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8780091)

  • 1. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
    Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC
    Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Clin Neurol Neurosurg; 1989; 91(4):303-9. PubMed ID: 2555090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
    Pahwa R; Busenbark K; Huber SJ; Michalek D; Hubble JP; Koller WC
    Neurology; 1993 Apr; 43(4):677-81. PubMed ID: 8469321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
    Hutton JT; Albrecht JW; Román GC; Kopetzky MT
    Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
    Hsu A; Yao HM; Gupta S; Modi NB
    J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
    Koller WC; Hutton JT; Tolosa E; Capilldeo R
    Neurology; 1999 Sep; 53(5):1012-9. PubMed ID: 10496260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
    Cedarbaum JM; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell FH
    J Neural Transm Park Dis Dement Sect; 1990; 2(3):205-13. PubMed ID: 2257060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.